Boehringer Ingelheim o phatlalalitse kajeno hore US Food and Drug Administration (FDA) e file Breakthrough Therapy Designation ho mofuta oa eona oa kalafo oa lipatlisiso, BI 1015550, bakeng sa kalafo ea idiopathic pulmonary fibrosis (IPF). BI 1015550 ke inhibitor ea molomo, phosphodiesterase 4B (PDE4B) e nang le monyetla oa ho sebetsana le pulmonary fibrosis - leqeba le ke keng la thijoa la lisele tsa matšoafo le amang ts'ebetso ea matšoafo hampe - le ho ruruha ho amanang le mafu a tsoelang pele a mats'oafo a "fibrosing interstitial" (ILDs).
"Ntšetso-pele e potlakileng ea BI 1015550 ke karolo ea leqhubu le latelang la Boehringer Ingelheim la mekhoa e mecha ea phekolo bakeng sa mafu a matšoafo a matšoafo a reretsoeng ho boloka ts'ebetso ea matšoafo le ho ntlafatsa bophelo ba bakuli," ho boletse Thomas Seck, MD, motlatsi oa motlatsi oa mopresidente, Meriana le Litaba tsa Taolo. Boehringer Ingelheim Pharmaceuticals, Inc. “BI 1015550 e emetse molek'hule oa pele sehlopheng sa PDE4B inhibitors e ntseng e ithutoa bakeng sa IPF le li-ILD tse ling tse tsoelang pele tsa fibrosing. Re thehile holim'a lefa la rona ho pulmonary fibrosis mme re ntse re sebetsa ho latela sephetho le tlhaiso-leseling ea bongaka ka sepheo sa hore moriana ona o mocha o ka fihlela bakuli kapele kamoo ho ka khonehang. ”
